Table 5.
Amino acid substitutions emerging in Nsp8, Nsp10, Nsp13, and Nsp14 at post-baseline in the severe COVID-19 study.
| Change from Baseline | Number of Participants with Baseline and Post-Baseline Sequencing Data | ||||
|---|---|---|---|---|---|
| A | B | Total (n = 12) |
|||
| RDV for up to 5 Days (n = 0) |
RDV for up to 10 Days (n = 0) |
Non-Randomized Expanded Access (RDV for up to 10 Days) (n = 6) a |
Invasive Mechanical Ventilation (RDV for up to 10 Days) (n = 6) |
||
| Nsp8 A89T | NA | NA | 0 | 1/6 (17%) | 1/9 (11%) |
| Nsp13 F581L | NA | NA | 1/4 (25%) | 0 | 1/10 (10%) |
| Nsp14 T21R | NA | NA | 0 | 1/6 (17%) | 1/11 (9%) |
| Nsp14 I101V + A287V | NA | NA | 1/5 (20%) | 0 | 1/11 (9%) |
NA = not applicable; RDV = remdesivir. a The denominator is based on sequencing coverage for Nsp8, Nsp10, Nsp13, and Nsp14 at baseline and post-baseline and could vary in the different regions of the polymerase complex.